PRM17 - An evaluation of medication errors in a large teaching hospital

Abstract

early treatment response evaluation in 82 (67.21%) of the patients, for staging in 65 (53.28%) patients, late treatment responseevaluation in 48 (39.34%) patients, for restaging in 40 (32.79%) patients. PET/CT was not used for diagnosis and radiation treatment response evaluation. Major histologic subtype was found to be infiltrating ductal carcinoma (IDC) (91%). liver was the most common metastatic site among all (41 patients) 85.37% in 35 patients, lung in 30 patients (73.17%), bone in 25 patients (60.98%), around 3 patients were having lesions in brain, adrenal and ovaries, around (4.88%) 2 patients were presented with lesion in atrium. Recurrence was present in 31(76%) patients, chest wall invasion in 10 patients (24%). Maximum number of patients around 21 patients had lesions in ipsilateral axillary nodes (51.22%), 16 in supraclavicular nodes (39.02%) and 13 patients (31.71%) in contralateral nodes. Treatment plan was altered in 55 patients (45.08%), whereas supported in 67 patients (54.92%). CONCLUSIONS: The clinical utility of PET/CT may lead to a change in the routine diagnostic algorithm and follow-up protocols for patients with cancer by providing correct and early diagnosis of recurrence as well as by establishing its precise significance for further clinical management.